FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

Size: px
Start display at page:

Download "FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS"

Transcription

1 FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs during the year. If DHMC/CHP+ removes drugs from the formulary, or adds a restriction to an existing formulary drug, such as prior authorization, quantity limits and/or step therapy, [and/or moves a drug to a higher cost-sharing tier], DHMC/CHP+ will notify you of the change at least 10 days before the date that the change becomes effective. If the Food and Administration (FDA) deems a drug on the formulary to be unsafe, or the drug s manufacturer removes the drug from the market, DHMC/CHP+ will immediately remove the drug from the formulary. The table below outlines previous and/or recent changes to the formulary. The newest updates are highlighted in yellow. For questions or if you would like more information related to these changes please call the DHMC/CHP+ Pharmacy Services Department at or FORMULARY ABBREVIATIONS (Explanations can be found on the website in the DHMC/CHP+ Formulary and Pharmaceutical Management Procedures) LA = (must be filled at DH Pharmacy or PA Required); PA = ; QL = ; ST = Ledipasvir/ Sofosbuvir Sofosbuvir/ Velpatasvir Albendazole Estradiol Valerate Vials Lyrica No Updates for th Quarter of 018 Atomoxetine Generic for Harvoni Generic for Epclusa Generic Generic LA, QL, PA 01/01/019 LA, QL, PA 01/01/019 Generic for Generic 1 01/01/019 Albenza Addition Addition 1 01/01/019 ; Gabapentin or Duloxetine LA, QL, ST 01/01/019 10/01/018 Addition Addition LA, QL 07/01/018

2 Fondaparinux Syringes Buprenorphine/ Naloxone Film 8 mg/ mg Film Praziquantel Atovaquone/ Proguanil Addition Addition Generic Generic for Suboxone 8 mg/ mg Film Generic for Generic Biltricide from to 1; Generic for Norvir Cost LA, QL 07/01/018 LA, QL 07/01/018 LA 07/01/018 1 QL 07/01/018 Ritonavir Generic LA 0/01/018 Tacrolimus Addition Addition LA 0/01/018 Tradjenta Addition Addition LA, QL 0/01/018 Jentadueto Addition Addition LA, QL 0/01/018 Narcan Nasal Addition Addition QL 0/01/018 Spray Buprenorphine Addition Addition LA, QL 0/01/018 Sublingual Estradiol Vaginal Addition Addition 1 QL 0/01/018 Cream Efavirenz Generic for Generic LA 0/01/018 Sustiva Tenofovir Generic for Generic LA 0/01/018 Disoproxil Viread Fumarate Atazanavir Generic for Generic LA 0/01/018 Reyataz Aripiprazole LA, QL 01/01/018 Metformin Cost Metformin LA 01/01/018 (Generic for Fortamet) from 1 to ; Extended- Release (Generic for Glucophage XR) Lyrica Addition Addition LA, QL, PA 01/01/018 Oxycodone Addition Addition One Formulary Long-Acting Opioid LA, QL, ST 01/01/018

3 Victoza Pens Addition Addition One Formulary Diabetic Medication Priftin Addition Addition Abacavir Oral Generic Generic Solution Ziagen Eletriptan Imiquimod Enoxaparin Generic Relpax from to 1; from to ; Generic Sumatriptan and zolmitriptan LA, QL, ST 01/01/018 LA 01/01/018 LA 10/01/017 LA, QL, ST 10/01/ /01/017 Mavyret Addition Addition Entresto Addition Addition Risperdal Consta Addition Addition Oral Syringes Risperidone Jardiance Addition Addition One Formulary Diabetic Medication Codeine Products Tramadol Ondansetron and Oral- Disintegrating Norvir Age Updated to 1 Years and Older Age for 1 Years and Older Increased from 0 Per 0 Days to 90 Per 0 Days from to FDA Safety Warning Labeling FDA Safety Warning Labeling QL 10/01/017 LA, QL, PA 10/01/017 LA, QL 07/01/017 LA, QL, ST 07/01/017 LA, QL, ST 07/01/017 Age, QL 07/01/017 Age, QL 07/01/017 QL 07/01/017 LA 07/01/017

4 Vivitrol Vials Antipyrine/ Benzocaine Otic Solution Atropine Ophthalmic Solution Cytra-K Crystals and Oral Solution Donnatal Elixir and Esterified Estrogens/ Methyltestosterone Hydrocortisone/ Pramoxine Rectal Cream Phenazopyridine Tacrolimus Ointment from 1 to ; Regulatory Requirement Vyvanse Addition Addition Amphetamine Salts and Xarelto 0 mg Venlafaxine Fenofibrate Doxycycline and Duloxetine LA, QL 07/01/017 LA 07/01/017 Addition Addition Topical Corticosteroids LA, QL, ST 0/01/017 LA, QL, ST 0/01/017 or Methylphenidate LA, QL 0/01/017 Increased Increased and from to 1 Cost QL 0/01/017 QL 0/01/017 QL 0/01/017 1 QL 0/01/017

5 Aranesp Syringes and Vials Leukine Syringes and Vials Neupogen Syringes and Vials Epinephrine Auto- Injectors Generic Epipen and Epipen Jr LA 01/01/017 LA 01/01/017 LA 01/01/017 Generic 1 QL 01/01/017 Descovy Addition Addition LA 01/01/017 Genvoya Addition Addition LA 01/01/017 Odefsey Addition Addition LA 01/01/017 Vemlidy Addition Addition LA 01/01/017 Vivitrol Vials Addition Addition LA, QL, PA 01/01/017 Oseltamivir Generic Tamiflu Generic 1 QL 01/01/017 Abacavir/ Lamivudine Aripiprazole Lidocaine 5% Ointment Generic Epzicom ; from 1 to and Limited Access and Generic Cost Clozapine, Olanzapine, Quetipaine, Risperidone, Ziprasidone Lidocaine % Cream LA 01/01/017 LA, QL, PA 01/01/017 LA, QL 01/01/017

6 Sovaldi Deletion Cost Epclusa, Harvoni, Zepatier 01/01/017 Epclusa Addition Addition LA, PA, QL 10/01/016 Zepatier Addition Addition LA, PA, QL 10/01/016 Mesalamine Generic Generic 10/01/016 Delayed-Release Asacol HD Colchicine Addition Addition LA, QL, ST 10/01/016 Guanfacine Acitretin Rosuvastatin ; Generic Crestor LA, QL 10/01/016 Methotrexate LA, ST 10/01/016 Generic LA, QL 07/01/016 Modafinil Addition Addition QL 07/01/016 Complera Addition Addition LA 07/01/016 Celecoxib QL 07/01/016 Diclofenac Gel Generic Voltaren Gel Generic 1 QL 07/01/016 Levitra Age QL 07/01/016

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS

FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs

More information

Formulary Updates to DHMP Commercial Plans DHHA: DMC/DMC-HP/POS DHMO/HDHP: City & County of Denver/Denver Police/DERP

Formulary Updates to DHMP Commercial Plans DHHA: DMC/DMC-HP/POS DHMO/HDHP: City & County of Denver/Denver Police/DERP 1 Formulary Updates to DHMP Commercial Plans DHHA: DMC/DMC-HP/POS DHMO/HDHP: City & County of Denver/Denver Police/DERP Denver Health Medical Plan (DHMP) may add or remove drugs from the formulary or make

More information

FORMULARY ABBREVIATIONS

FORMULARY ABBREVIATIONS 1 Formulary Updates to DHMP Commercial Plans DMC/DMC-HP/POS DHMO/HDHP: City & County of Denver/Denver Police/DERP Denver Public Schools: DHMO/1300/2600/3500 Denver Health Medical Plan (DHMP) may add or

More information

Step Therapy Approval Criteria

Step Therapy Approval Criteria Effective Date: 01/01/2019 This document contains for the following medications: 1. Colcrys (colchicine) 2. Dovonex (calcipotriene) 3. Enbrel (etanercept) 4. Humira (adalimumab) 5. Imitrex Injection vial

More information

Step Therapy Approval Criteria

Step Therapy Approval Criteria Effective Date: 01/01/2018 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Dovonex (calcipotriene) 3. Enbrel (etanercept) 4. Humira (adalimumab)

More information

2017 Formulary Changes Year to Date

2017 Formulary Changes Year to Date 2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or

More information

May 2016 P & T Updates

May 2016 P & T Updates Commercial Triple Tier 4th Tier Applicabl e Traditional Detailed s 2 films - DESCOVY 2 2 1 tablet NARCAN 2 2 ODEFSEY 2 2 1 tablet REPATHA 2 2 HoFH: 3 ml per 28 ROSUVASTATIN 1 1 - UPTRAVI 3 2 - Alternatives

More information

APREPITANT ARMODAFINIL BELSOMRA BUPAP BUPRENORPHINE HCL BUTALBITAL-ACETAMINOPHEN BUTALBITAL-APAP-CAFF-COD BUTALBITAL-APAP-CAFFEINE

APREPITANT ARMODAFINIL BELSOMRA BUPAP BUPRENORPHINE HCL BUTALBITAL-ACETAMINOPHEN BUTALBITAL-APAP-CAFF-COD BUTALBITAL-APAP-CAFFEINE APREPITANT Aprepitant Oral Capsule 125, 40, 80 Aprepitant Oral Capsule 80 & 125 Quantity Limit: 8 EA Per 30 Days Quantity Limit: 12 EA Per 30 Days ARMODAFINIL Armodafinil Oral Tablet 150, 200, 250, 50

More information

Aetna Better Health of Illinois Medicaid Formulary Updates

Aetna Better Health of Illinois Medicaid Formulary Updates October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary

More information

Kansas Health Advantage (HMO SNP) 2018 Formulary Quantity Limit Criteria

Kansas Health Advantage (HMO SNP) 2018 Formulary Quantity Limit Criteria APREPITANT Kansas Health Advantage (HMO SNP) 2018 Formulary Aprepitant Oral Capsule 125, 40, 80 Aprepitant Oral Capsule 80 & 125 Quantity Limit: 8 EA Per 30 Days Quantity Limit: 12 EA Per 30 Days ARMODAFINIL

More information

2018 CareOregon Advantage Part D Formulary Changes

2018 CareOregon Advantage Part D Formulary Changes 2018 CareOregon Advantage Part D Formulary Changes Abbreviations: AGE = Age Restriction; PA = Prior Authorization Required; QL = Quantity Limit; ST = Step Therapy Required; LD = Limited Distribution; BvD

More information

Tribute 2018 Formulary 2018 Quantity Limit Criteria

Tribute 2018 Formulary 2018 Quantity Limit Criteria APREPITANT Aprepitant Oral Capsule 125, 40, 80 Aprepitant Oral Capsule 80 & 125 Quantity Limit: 8 EA Per 30 Days Quantity Limit: 12 EA Per 30 Days ARMODAFINIL Armodafinil Oral Tablet 150, 200, 250, 50

More information

Tribute 2018 Formulary 2018 Quantity Limit Criteria

Tribute 2018 Formulary 2018 Quantity Limit Criteria APREPITANT Aprepitant ORAL CAPSULE 125, 40, 80 Aprepitant Oral CAPSULE 80 & 125 Quantity Limit: 8 EA Per 30 Days Quantity Limit: 12 EA Per 30 Days ARMODAFINIL Armodafinil ORAL TABLET 150, 200, 250, 50

More information

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES

BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES BLUE SHIELD OF CALIFORNIA MARCH 2016 STANDARD DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.

More information

PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017

PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017 PHARMACY AND THERAPEUTICS COMMITTEE 4 th Quarter 2017 A meeting of the Health Partners Pharmacy and Therapeutics (P&T) Committee was held on September and December 2017. The following are the recommendations

More information

Pharmacy and Therapeutics (P&T) Committee Provider Update

Pharmacy and Therapeutics (P&T) Committee Provider Update Pharmacy and Therapeutics (P&T) Committee Provider Update FIRST QUARTER 2017 P&T Committee Decisions effective March 1, 2017 Dear Healthcare Practitioner: The Presbyterian Health Plan, Inc., and Presbyterian

More information

Changes to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies

Changes to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies Changes to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies BlueCross BlueShield of South Carolina may add or remove drugs from the formulary during the year. If we remove drugs

More information

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTIDIABETIC AGENTS - MISCELLANEOUS ANTIDIABETIC AGENTS - MISCELLANEOUS GLYXAMBI 10 MG-5 MG GLYXAMBI 25 MG-5 MG INVOKAMET 150 MG-1,000 MG INVOKAMET 150 MG-500 MG INVOKAMET 50 MG-1,000 MG INVOKAMET 50 MG-500 MG INVOKAMET XR 150 MG-1,000 MG,

More information

Formulary Updates to DHMP Commercial Plans (POS/DMC/DMC-E/CSA/DERP/DPPA & DHMO:CSA/DERP/DPPA)

Formulary Updates to DHMP Commercial Plans (POS/DMC/DMC-E/CSA/DERP/DPPA & DHMO:CSA/DERP/DPPA) 1 Formulary Updates to DHMP Commercial Plans (POS/DMC/DMC-E/CSA/DERP/DPPA & DHMO:CSA/DERP/DPPA) Denver Health Medical Plan (DHMP) may add or remove drugs from the formulary or make changes to restrictions

More information

Drug Formulary Update, July 2016 Commercial and State Programs

Drug Formulary Update, July 2016 Commercial and State Programs Drug Formulary Update, July 2016 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,

More information

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications

Daclatasvir (Daklinza ) Drug Interactions with HIV Medications Daclatasvir/Sofosbuvir (Daklinza /Sovaldi TM ) Drug Interactions A Quick Guide for Clinicians April 2017 John J Faragon, PharmD, BCPS, AAHIVP Mechanism of Action and Route of Metabolism for Daclatasvir

More information

Medicare Part D 2012 Formulary Changes Service To Senior and Total Fit

Medicare Part D 2012 Formulary Changes Service To Senior and Total Fit Medicare Part D 2012 Formulary s Service To Senior and Total Fit Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization,

More information

2018 Formulary Notice of Change Prescription Drug Plans

2018 Formulary Notice of Change Prescription Drug Plans 2018 Formulary Notice of Change Prescription Drug Plans WellCare Prescription Insurance, Inc. Plans in all states: WellCare Classic (PDP) WellCare may add or remove drugs from our formulary during the

More information

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTIDIABETIC AGENTS - MISCELLANEOUS ANTIDIABETIC AGENTS - MISCELLANEOUS Glyxambi 10 mg-5 mg tablet Glyxambi 25 mg-5 mg tablet Invokamet 150 mg-1,000 mg tablet Invokamet 150 mg-500 mg tablet Invokamet 50 mg-1,000 mg tablet Invokamet 50 mg-500

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG FYCOMPA 0.5 MG/ML ORAL SUSPENSION FYCOMPA 10 MG FYCOMPA 12 MG FYCOMPA

More information

Drug Class Review Monograph GPI Class 12 Antivirals

Drug Class Review Monograph GPI Class 12 Antivirals Drug Class Review Monograph GPI Class 12 Antivirals Review Time Frame: 02/2016 04/2017 Previous Class Review: 05/2016 Background: Antiviral agents are used to treat infections caused by viruses, including,

More information

Peach State Health Plan routinely reviews the medications available on the Preferred Drug

Peach State Health Plan routinely reviews the medications available on the Preferred Drug Effective date: December 27, 2016 Peach State Health Plan Preferred Drug List (PDL) Updates Q4 2016 Peach State Health Plan routinely reviews the medications available on the Preferred Drug List (PDL).

More information

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017

Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017 Medicare Part D Drugs that Require Step Therapy Effective 12/01/2017 Providers may call the Pharmacy Help Desk at 800-641-8921 for more information or questions about criteria. The formulary may change

More information

Drug Formulary Update, January 2018 Commercial and State Programs

Drug Formulary Update, January 2018 Commercial and State Programs Drug Formulary Update, January 2018 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,

More information

Step Therapy Requirements

Step Therapy Requirements Step Therapy Requirements Denver Health Medicare Choice (HMO SNP)/Medicare Select (HMO) Effective: 09/01/2017 Updated 08/2017 ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet

More information

Medicare Part D 2017 Formulary Changes OC Preferred

Medicare Part D 2017 Formulary Changes OC Preferred Medicare Part D 2017 Formulary Changes OC Preferred Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization,

More information

ANTIDIABETIC AGENTS - MISCELLANEOUS

ANTIDIABETIC AGENTS - MISCELLANEOUS ANTIDIABETIC AGENTS - MISCELLANEOUS Glyxambi 10 mg-5 mg tablet Glyxambi 25 mg-5 mg tablet Invokamet 150 mg-1,000 mg tablet Invokamet 150 mg-500 mg tablet Invokamet 50 mg-1,000 mg tablet Invokamet 50 mg-500

More information

Partners Notice of Change March 2017

Partners Notice of Change March 2017 New Added Products: Effective 3/1/2017 Drug Reason Tier Restrictions abacavir 600 mg-lamivudine 300 QL ADRENACLICK 0.15 MG/0.15 ML INJECTION,AUTO- INJECTOR ADRENACLICK 0.3 MG/0.3 ML INJECTION, AUTO- INJECTOR

More information

Step Therapy Approval Criteria

Step Therapy Approval Criteria Effective Date: 10/01/2016 This document contains Step Therapy Approval Criteria for the following medications: 1. Colcrys (colchicine) 2. Cymbalta (duloxetine) 3. Dovonex (calcipotriene) 4. Enbrel (etanercept)

More information

Pharmacy Medical Necessity Guidelines: Hepatitis C Virus

Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Pharmacy Medical Necessity Guidelines: Hepatitis C Virus Effective: January 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX)

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension

More information

ALLERGIC CONJUNCTIVITIS AGENTS

ALLERGIC CONJUNCTIVITIS AGENTS 2018 5 Tier Standard- Keystone First VIP Choice Document: 2018 Step Therapy Formulary ID: 18390 Last Updated: 04/2018 Effective Date: 05-01-2018 ALLERGIC CONJUNCTIVITIS AGENTS epinastine 0.05 % eye drops

More information

Alprazolam 0.25mg, 0.5mg, 1mg tablets

Alprazolam 0.25mg, 0.5mg, 1mg tablets Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service

More information

2018 Medicare Part D Formulary Change

2018 Medicare Part D Formulary Change 2018 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy

More information

NOTIFICATION OF FORMULARY CHANGES

NOTIFICATION OF FORMULARY CHANGES NOTIFICATION OF CHANGES The following summary describes changes to the 2018 Presbyterian Senior Care (HMO)/(HMO-POS), Presbyterian MediCare PPO and formularies. The formulary may change at any time. You

More information

2018 Formulary Update

2018 Formulary Update MEDICARE ADVANTAGE BlueShield of Northeastern New York 2018 Formulary Update BlueShield of Northeastern New York has updated its formulary (drug list) since its original publication in January 2018. This

More information

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017

Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017 Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017 DRUG LIST CHANGES Based on the availability of new prescription medications and Prime s National Pharmacy and Therapeutics Committee

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET APTIOM 800 MG TABLET BANZEL 200 MG TABLET BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG TABLET FYCOMPA 0.5 MG/ML ORAL SUSPENSION

More information

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.

CRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication. ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE

More information

Step Therapy Requirements. Effective: 1/1/2019

Step Therapy Requirements. Effective: 1/1/2019 Effective: 1/1/2019 Updated 1/2019 AMANTADINE ER Sharp Health Plan (HMO) OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED RELEASE PRIOR CLAIM FOR AMANTADINE

More information

JULY 2017 ADDITIONS. NP Thyroid 120mg NP Thyroid 15mg JUNE 2017 CHANGES

JULY 2017 ADDITIONS. NP Thyroid 120mg NP Thyroid 15mg JUNE 2017 CHANGES APRIL 2017 Ivermectin, Pin-X and Reeses (Pyrantel Pamoate) Selzentry 25mg and 75mg tablets Linzess 72 mcg capsule-with QLL Levalbuterol Tartrate Inhal Aerosol (Generic Xopenex HFA) with ST & QLL Jentadueto

More information

ANTICONVULSANTS. Details

ANTICONVULSANTS. Details ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension

More information

Coverage Guideline/Policy & Procedure Status Revision Summary Description

Coverage Guideline/Policy & Procedure Status Revision Summary Description Coverage Guideline/Policy & Procedure Status Revision Summary Description HIM.PA.49 lacosamide (Vimpat) Added max dose. HIM.PA.50 isotretinoin (Claravis, Sotret, Amensteem, Myorisan) HIM.PA.51 oral bisphosphonates

More information

2018 Medicare Part D Formulary Change

2018 Medicare Part D Formulary Change 2018 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy

More information

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details AMANTADINE ER OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE OSMOLEX ER 258 MG TABLET, PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.

More information

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details AMANTADINE ER OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED RELEASE PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS. 1 ANTICONVULSANTS

More information

November 2018 P & T Updates

November 2018 P & T Updates November 2018 P & T Updates Commercial Triple Tier 4th Tier Applicable Traditional Prior Auth AIMOVIG 3 2 Detailed s 70 mg per month: 2 ml per 60 days 140 mg per month: 2 ml per 30 days AJOVY 3 2 4.5 ml

More information

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details

AMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details AMANTADINE ER OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE OSMOLEX ER 258 MG TABLET, PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.

More information

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017 VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 01/01/2017 Updated 12/23/2016 ANTICONVULSANTS Aptiom 200 mg tablet Potiga 200 mg tablet Aptiom 400 mg tablet Potiga 300 mg tablet Aptiom

More information

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily

HIV MEDICATIONS AT A GLANCE. Atripla 600/200/300 mg tablet tablet daily. Complera 200/25/300 mg tablet tablet daily HIV MEDICATIONS AT A GLANCE Generic Name Trade Name Strength DIN Usual Dosage Single Tablet Regimen (STR) Products Efavirenz/ Emtricitabine/ rilpivirine/ elvitegravir/ cobicistat/ alafenamide Emtricitabine/

More information

FirstCarolinaCare Insurance Company. Step Therapy Requirements

FirstCarolinaCare Insurance Company. Step Therapy Requirements FirstCarolinaCare Insurance Company Step Therapy Requirements Effective: 12/01/2018 ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION

More information

Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir

Mercy Care Plan. Acyclovir Ointment. Products Affected. acyclovir ointment 5 % external Details. Criteria. Requires use of oral Acyclovir Acyclovir Ointment Mercy Care Plan acyclovir ointment 5 % external Requires use of oral Acyclovir 1 Adcirca ADCIRCA TABLET 20 MG ORAL Requires use of Sildenafil 2 Albenza ALBENZA TABLET 200 MG ORAL Requires

More information

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E

Santa Clara Family Health Plan Cal MediConnect Formulary. List of Step Therapy Requirements Effective: 12/01/ E Santa Clara Family Health Plan Cal MediConnect Formulary List of Step Therapy Requirements Effective: 12/01/2018 13027.12E ANTICONVULSANTS APTIOM 200 MG TABLET APTIOM 400 MG TABLET APTIOM 600 MG TABLET

More information

Step Therapy Approval Criteria

Step Therapy Approval Criteria Effective Date: 07/01/2015 This document contains for the following medications: 1. Ambien CR (zolpidem ER) 2. Chantix Continuing Month (varenicline) 3. Chantix Starting Month (varenicline) 4. Cymbalta

More information

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 04/01/2019 VNSNY CHOICE FIDA Complete Step Therapy Requirements Effective: 04/01/2019 Updated 03/2019 AMANTADINE ER OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED

More information

Emblem Medicaid 3Q18 Formulary Updates

Emblem Medicaid 3Q18 Formulary Updates ALKERAN 2 MG TABLET Removed from Formulary 7/9/2018 AMITIZA 24 MCG CAPSULES Removed from Formulary 7/9/2018 AMITIZA 8 MCG CAPSULE Removed from Formulary 7/9/2018 avo cream topical emulsion Removed from

More information

Calgary Long Term Care Formulary

Calgary Long Term Care Formulary Page 1 of 10 Calgary Long Term Care Formulary Pharmacy & Therapeutics November 2018 Highlights https://www.albertahealthservices.ca/info/page4071.aspx Page 2 of 10 Contents November 2018... 3 Formulary

More information

ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) PROGRAM UPDATE

ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) PROGRAM UPDATE ADDICTION AND RECOVERY TREATMENT SERVICES (ARTS) PROGRAM UPDATE Matthew Keats, MD, MMM Behavioral Health Medical Director Virginia Department of Medical Assistance Services October 26, 2017 www.dmas.virginia.gov

More information

Medicines Formulary BNF Section 4 Central Nervous System

Medicines Formulary BNF Section 4 Central Nervous System Medicines BNF Section 4 4.1 Hypnotics and anxiolytics Chloral Hydrate 500mg/5ml Solution Clomethiazole 192mg Capsules Lormetazepam Tablets Melatonin Capsules Nitrazepam Suspension Nitrazepam Tablets Temazepam

More information

HIV Drugs and the HIV Lifecycle

HIV Drugs and the HIV Lifecycle HIV Drugs and the HIV Lifecycle Together, we can change the course of the HIV epidemic one woman at a time. #onewomanatatime #thewellproject All HIV drugs work by interrupting different steps in HIV's

More information

Medicare Part D 2017 Formulary Changes Service To Senior

Medicare Part D 2017 Formulary Changes Service To Senior Medicare Part D 2017 Formulary s Service To Senior Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization,

More information

True Health New Mexico List of Medications with Quantity Limits

True Health New Mexico List of Medications with Quantity Limits True Health New Mexico List of Medications with Quantity Limits Specialty Medications Contact True Health New Mexico Pharmacy Services at 1-866- 341-8561 for quantity limits on specialty medications. Maximum

More information

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria

ANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria ANTIDEPRESSANTS Trintellix 10 mg tablet Trintellix 20 mg tablet Trintellix 5 mg tablet Viibryd 10 mg (7)-20 mg (23) tablets in a dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet

More information

Commercial Formulary and Utilization Management Program Updates for January 2017 Producer Communication #782 Issued November 10, 2016

Commercial Formulary and Utilization Management Program Updates for January 2017 Producer Communication #782 Issued November 10, 2016 Commercial and Utilization Management Program Updates for January 2017 Producer Communication #782 Issued November 10, 2016 Message The Capital BlueCross Pharmacy & Therapeutics (P&T) Committee, consisting

More information

DRUG TREND REPORT. WellDyneRx ANNUAL 1 2% 34% WellDyneRx. Diabetes MS Oncology Asthma/COPD HIV. Pain/inflammation. High Blood Choles Attention Disorde

DRUG TREND REPORT. WellDyneRx ANNUAL 1 2% 34% WellDyneRx. Diabetes MS Oncology Asthma/COPD HIV. Pain/inflammation. High Blood Choles Attention Disorde WellDyneRx 34% 1 2% Inflammatory Con Diabetes MS Oncology Asthma/COPD High Blood Pressu HIV Pain/inflammation High Blood Choles Attention Disorde Inflammatory Con Diabetes MS Oncology Asthma/COPD High

More information

Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)

Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017) Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017) The Capital BlueCross formulary is a reference list of prescription drugs that contains a wide range of generic and brand drugs that have

More information

Quarterly pharmacy formulary change notice

Quarterly pharmacy formulary change notice Quarterly pharmacy formulary change notice Summary of change: The Pharmacy and Therapeutics Committee (P&T) reviewed and approved the formulary changes listed in the table below on March 29, 2016. What

More information

Step Therapy Requirements. Effective: 05/01/2018

Step Therapy Requirements. Effective: 05/01/2018 Step Therapy Requirements Effective: 05/01/2018 ANTIDEPRESSANTS TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK VIIBRYD 10 MG

More information

Cynthia B. Jones, Director Department of Medical Assistance Services (DMAS)

Cynthia B. Jones, Director Department of Medical Assistance Services (DMAS) Department of Medical Assistance Services 600 East Broad Street, Suite 1300 Richmond, Virginia 23219 MEDICAID MEMO http://www.dmas.state.va.us TO: All Prescribing Providers, Pharmacists, and Managed Care

More information

Pharmacy Updates Summary

Pharmacy Updates Summary All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines

More information

Medicare Part D 2017 Formulary Changes OC Preferred

Medicare Part D 2017 Formulary Changes OC Preferred Medicare Part D 017 Formulary s OC Preferred Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization, quantity

More information

2015 Step Therapy Prior Authorization Medical Necessity Guidelines

2015 Step Therapy Prior Authorization Medical Necessity Guidelines Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154

More information

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017

VNSNY CHOICE FIDA Complete Step Therapy Requirements. Effective: 01/01/2017 Effective: 01/01/2017 Updated 11/2016 ANTI-INFLAMMATORY AGENTS - GI DIPENTUM PRIOR CLAIM FOR BALSALAZIDE OR APRISO WITHIN THE PAST 120 DAYS. ANTICONVULSANTS APTIOM BANZEL FYCOMPA GABITRIL OXTELLAR XR POTIGA

More information

PHOTOFRIN Porfimer ALL LOB: ADD NF PA FETZIMA Levomilnacipran 20-40mg Titration pack ALL LOB: Add NF with PA

PHOTOFRIN Porfimer ALL LOB: ADD NF PA FETZIMA Levomilnacipran 20-40mg Titration pack ALL LOB: Add NF with PA March 24, 2014 Subject: February 13, 2014 LA Care PT&T Updates Dear Practitioner: We would like to thank you for providing quality services to our LA Care Medi-Cal (LAC01), Healthy Kids (LAC02), Healthy

More information

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives

PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select October 1, 2018 Updates Drug Name efavirenz 600mg (Brand = Sustiva ) trientine (Brand = Syprine ) hydrocortisone lot 0.1% (Brand = Locoid ) sumatriptan-naproxen

More information

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) 207 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Plus Plan (HMO) H5087-002, H5087-07 This is a listing of the changes that have occurred in our formulary.

More information

Medicare Part D 2017 Formulary Changes OC Preferred

Medicare Part D 2017 Formulary Changes OC Preferred Medicare Part D 2017 Formulary s OC Preferred Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization, quantity

More information

Pharmacy and Therapeutics (P&T) Committee Provider Update

Pharmacy and Therapeutics (P&T) Committee Provider Update Pharmacy and Therapeutics (P&T) Committee Provider Update SECOND QUARTER 2018 P&T Committee Decisions Effective June 1, 2018 Dear Healthcare Practitioner: The Presbyterian Health Plan, Inc., and Presbyterian

More information

Step Therapy Requirements. Effective: 11/01/2018

Step Therapy Requirements. Effective: 11/01/2018 Effective: 11/01/2018 Updated 10/2018 ANTIDEPRESSANTS Sharp Health Plan (HMO) TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK

More information

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)

2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) 2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Best Plan (HMO) H5087-005 This is a listing of the changes that have occurred in our formulary. Please

More information

SUPPORTING OUR PROVIDER PARTNERS THROUGH COMMUNICATION AND COLLABORATION. DATE July 2016 ISSUE 3

SUPPORTING OUR PROVIDER PARTNERS THROUGH COMMUNICATION AND COLLABORATION. DATE July 2016 ISSUE 3 SUPPORTING OUR PROVIDER PARTNERS THROUGH COMMUNICATION AND COLLABORATION. DATE July 2016 ISSUE 3 HELPFUL NUMBERS FOR PROVIDERS Magellan: 1-800-846-7971 Bin: 016523 Processor control: 747 HELPFUL NUMBERS

More information

PATIENT INFORMATION VIREAD

PATIENT INFORMATION VIREAD PATIENT INFORMATION VIREAD (VEER-ee-ad) (tenofovir disoproxil fumarate) tablets and oral powder Read this Patient Information before you start taking VIREAD and each time you get a refill. There may be

More information

PPHP 2017 Formulary 2017 Step Therapy Criteria

PPHP 2017 Formulary 2017 Step Therapy Criteria ARISTADA Aristada Prefilled Syringe 1064 MG/3.9ML Intramuscular Aristada Prefilled Syringe 441 MG/1.6ML Intramuscular Aristada Prefilled Syringe 662 MG/2.4ML Intramuscular Aristada Prefilled Syringe 882

More information

UPDATE Ohana QUEST Integration Medicaid

UPDATE Ohana QUEST Integration Medicaid UPDATE Ohana QUEST Integration Medicaid Preferred Drug List June 29, 2015 Dear Provider: At the June 04, 2015 WellCare Pharmacy & Therapeutics Committee meeting, it was decided that the following changes

More information

Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters

Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Guidance for Non-HIV-Specialized Providers Caring for Persons with HIV Displaced by Disasters Visit the AIDSinfo website to access the most up-to-date guideline. Register for e-mail notification of guideline

More information

Calgary Long Term Care Formulary. Pharmacy & Therapeutics. February 2015

Calgary Long Term Care Formulary. Pharmacy & Therapeutics. February 2015 Calgary Long Term Care Formulary Pharmacy & Therapeutics February 2015 Highlights http://www.albertahealthservices.ca/4070.aspx 1 Contents February 2016... 3 Added Product(s)... 3 Not Listed, Delisted

More information